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Lymphatic complications are common side effects of
mammalian target of rapamycin (mTOR) inhibitor-based
immunosuppression in kidney transplantation. Therefore, we
investigated whether the mTOR inhibitor rapamycin, besides
its known antihemangiogenic effect, also impedes
regenerative lymphangiogenesis. In a murine skin flap
model, rapamycin impaired recovery of lymphatic flow across
surgical incisions resulting in prolonged wound edema in
these animals. Importantly, the antilymphangiogenic effect
of rapamycin was not related to a general inhibition of
wound healing as demonstrated an in vivo MatrigelTM
lymphangiogenesis assay and a model of lymphangioma.
Rapamycin concentrations as low as 1 ng/ml potently
inhibited vascular endothelial growth factor (VEGF)-C driven
proliferation and migration, respectively, of isolated human
lymphatic endothelial cells (LECs) in vitro. Mechanistically,
mTOR inhibition impairs downstream signaling of VEGF-A as
well as VEGF-C via mTOR to the p70S6 kinase in LECs. In
conclusion, we provide extensive experimental evidence for
an antilymphangiogenic activity of mTOR inhibition
suggesting that the early use of mTOR inhibitor following
tissue injury should be avoided. Conversely, the
antilymphangiogenic properties of rapamycin and its
derivates may provide therapeutic value for the prevention
and treatment of malignancies, respectively.
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In the vast majority of tissues and organs, the lymphatic
network is responsible for the removal of interstitial protein
and fluid, thereby maintaining the interstitial fluid balance
and providing lymphatic clearance of macromolecules.1
Disintegration of the lymphatic drainage by chronic inflam-
mation, infection, trauma, or surgical procedures can give
rise to lymphedema and lymphatic malformations which
may result in large cystic structures accumulating lymphatic
fluid (lymphoceles).1 In addition to its role in fluid drainage,
the lymphatic system also represents an important route for
circulating immune cells that function in immune surveil-
lance and for metastatic dissemination of tumor cells via pre-
existing and possibly also via newly formed lymphatic
vessels.2 Under physiological conditions, the lymphatic
vasculature is a rather quiescent system, but several
pathological conditions such as lymphatic vessel injury,
inflammation, and cancer are characterized by lymphatic
vessel growth through stimulation by an orchestra of growth
factors.1,3
The recent introduction of rapamycin into clinical kidney
transplantation allowed transplant physicians to develop
novel immunosuppressive strategies providing adequate
immunosuppression for the transplant recipient while
avoiding the nephrotoxic side effects associated with
calcineurin inhibitor (CNI) therapy. Rapamycin forms a
complex with the FK506-binding protein complex that binds
with high affinity to the mammalian target of rapamycin
(mTOR). This interaction causes dephosphorylation and
inactivation of the p70S6 kinase, which, when activated,
stimulates the production of ribosomal components neces-
sary for protein synthesis and cell cycle progression. This
activity, which effectively blocks interleukin-2 stimulation of
lymphocyte division, is the basis for the successful clinical use
of rapamycin to prevent allograft rejection in organ
transplantation. However, a number of side effects may limit
the use of rapamycin in kidney transplantation. In addition
to general complications such as deregulation of the lipid
metabolism or the risk of thrombo- and leucopenia, a
number of complications have been reported that could be
well rationalized by a potential antilymphangiogenic activity
of mTOR inhibitors. Specifically, impaired wound healing
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and formation of lymphoceles have been associated with
rapamycin-based immunosuppression in kidney transplant
patients.4,5 Spontaneous formation of severe lymphedema
has also been observed in a number of patients,6–9 which
regressed after conversion to mTOR inhibitor-free immuno-
suppressant.
Indeed, these effects may be explained by the fact that
not only lymphocytes but also other cell types such as
smooth muscle cells and vascular endothelial cells depend on
mTOR signaling as a major downstream pathway of various
growth factors, energy sensors, hypoxia sensors as well as
cell components that are regulating cell growth and cell
division.10 Therefore, blockade of mTOR function mimics
deprivation of amino acids and, to a limited extent, lack
of growth factors. With respect to endothelial cells, mTOR
inhibition translates into a powerful antihemangiogenic
effect.11 We have previously shown that rapamycin blocks
blood vessels growth via inhibition of vascular endo-
thelial growth factor (VEGF)-A production and reduced
responsiveness of vascular endothelial cells to VEGF-A,
respectively.11,12 Considering the lymphatic complications
observed in kidney transplant patients, we hypothesized
that rapamycin may also inhibit lymphatic endothelial
cells (LECs) and, thus, may act as an antilymphangiogenic
agent.
RESULTS
Rapamycin inhibits lymphatic regeneration
The potential of rapamycin to delay regeneration of
lymphatic vessels after surgical incision was determined
using an epigastric skin flap model. Rapamycin markedly
inhibited the lymphatic drainage of skin flaps during 14 days
of treatment compared with control mice (Figure 1a and b;
Table 1). Specifically, the number of Patent Blue marked
lymphatic vessels crossing the flap border, which was used
as an indicator of reconstitution of lymph drainage, was
significantly reduced in rapamycin-treated mice compared
with controls. Drainage of Patent Blue to the regional,
sentinel lymph nodes was observed in all control mice
but only in 25% of the rapamycin-treated mice (Po0.01).
Consequently, this impaired lymphatic drainage was asso-
ciated with macroscopic lymphedema in all rapamycin-
treated animals whereas in control animals, lymphedema
was present in only 33% of the mice. Moreover, the ability
to reconstitute lymphatic drainage by recruiting collateral
vessels in the preserved caudal skin bridge was reduced in
rapamycin-treated animals, although this difference did
not reach a significant level. Consistently, the histological
analysis of the regenerative areas of the skin flaps (Figure 1c)
revealed a significantly lower number of lymphatic vessel
endothelial receptor (LYVE)-positive lymphatic vessels
in rapamycin-treated mice compared with control mice
(Figure 1d and e).
Rapamycin (5 mg/kg/day)Control
Control
Control
Control
1 32
4
5CV
1
Rapa
Control
Rapa
Rapa Rapa
Rapa
N
u
m
be
ro
f c
ro
ss
in
g
lym
ph
at
ic
ve
ss
el
s 10
8
6
4
2
0
P=0.004
day 14 day 28
P=0.023
Control
N
um
be
ro
f l
ym
ph
at
ic
ve
ss
e
ls 
pe
r m
icr
os
co
pi
c 
fie
ld
8
7
6
5
4
3
2
1
0
day 28
P<0.001
a
b
d e
c
Figure 1 | Rapamycin impairs regenerative lymphangiogenesis.
(a) Skin flap model. Images show Patent Blue lymphangiography in a
representative control and rapamycin-treated mouse on day 28
following skin incision. Numbers indicate crossing vessels. CV marks
collateral vessels. (b) The number of crossing vessels was significantly
reduced in rapamycin-treated mice. (c) Histological analysis of the
area of regeneration indicated a significant decrease in the number of
lymphatic vessels in mice treated with rapamycin. (d) Lymphatic
vessels were identified by immunostaining for the lymphatic marker
LYVE-1 (red) and nuclei were counterstained with DAPI.
(e) Representative images are depicted (nX5 each group).
Table 1 | Skin flap model – number of positive sentinel lymph
nodes, collateral vessels, and presence of lymphedema in
individual animals treated with vehicle or rapamycin
(nX5 per group)
Control
(C1, C2, C3,
C4, C5, C6)
Rapamycin
(5 mg/kg/day)
(R1, R2, R3,
R4, R5)
Positive sentinel
lymph nodesa (n)
2, 2, 2, 1, 1, 2 1, 0, 0, 1, 0 Po0.01
Collateral vessels (n) 1, 1, 3, 1, 2, 2 0, 0, 2, 1, 2 NS
Lymphedemab , , +, , +,  +, +, +, +, + Po0.05
NS, not significant.
aPatent Blue-positive right and/or left axillary lymph nodes.
b+, macroscopic lymphedema.
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Rapamycin inhibits invasion of lymphatic vessels into
MatrigelTM plugs
To provide further evidence that rapamycin inhibits lympha-
tic vessel regeneration independent of the well-known effects
on general wound healing, we used the MatrigelTM plug in
vivo assay. Two weeks after implantation of the MatrigelTM
plugs, the ingrowth of lymphatic vessels was visualized by
LYVE-1 immunostaining. In control animals, MatrigelTM
plugs were strongly invaded by LYVE-1-positive lymphatic
vessels (Figure 2). In contrast, in rapamycin-treated animals,
lymphatic neovascularization was markedly inhibited.
Rapamycin inhibits lymphangioma growth in de novo as well
as pre-existing lesions
The ability of rapamycin to delay lymphatic proliferation in
vivo was further investigated in a distinct murine model of
lymphangioma (benign tumor of LECs). In this model, two
consecutive intraperitoneal injections of incomplete Freund’s
adjuvant on days 0 and 1513 result in the development of
lymphangiomas in the peritoneal cavity (Figure 3a and b).
The lymphatic phenotype of the formed structures was
confirmed by staining for LYVE-1 (Figure 3c). Compared
with the control group, rapamycin-treated animals showed a
significantly reduced formation of lymphangiomas on day 28
(Figure 3d). This inhibition of lymphangioma growth was
confirmed in NMRI nu/nu mice, lacking T cells, indicating
that the antiproliferative effect of rapamycin is independent
of its immunosuppressive mode of action. In contrast, the
CNI cyclosporine had no significant inhibitory effect on the
de novo generation of lymphatic vessels (Figure 3e). More-
over, rapamycin was also capable of significantly decreasing
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Figure 3 | Rapamycin impairs lymphatic vessel formation. Lymphatic endothelial tumors were induced by intraperitoneal injection of
incomplete Freund’s adjuvant on days 0 and 15, respectively. (a) Area of angioma formation was assessed on day 28. (b and c) The tissue was
then processed for further histological analysis confirming the lymphatic nature of the formed tumors. (d) Lymphatic vessel structures were
identified by immunostaining for the lymphatic marker LYVE-1 (red) and nuclei were counterstained with DAPI. Quantification indicated a
significant reduction of angioma formation in rapamycin-treated animals (n¼ 7 each group). (e) The inhibitory effect of rapamycin on
lymphangioma growth was independent of its immunosuppressive mode of action as demonstrated in NMRI nu/nu mice. The CNI cyclosporine
had no inhibitory effect on the de novo generation of lymphatic vessels (e). Moreover, rapamycin was also capable of significantly decreasing
the tumor volume of pre-existing lymphangioma formations (f).
N
um
be
ro
f l
ym
ph
at
ic
ve
ss
e
ls 
pe
r m
icr
os
co
pi
c 
fie
ld
0
2
4
6
8
10
12
14
16
18
Control Rapamycin 
5 mg/kg/day
P=0.002
100 m
100 m
Figure 2 | Ingrowth of lymphatic vessels into MatrigelTM plugs was
significantly decreased by rapamycin (n¼ 5 each group)
independent of wound healing processes. Lymphatic vessels were
identified by immunostaining for LYVE-1 (red) and nuclei were
counterstained by DAPI (blue).
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the tumor volumes of pre-existing lymphangioma formations
(Figure 3f).
Rapamycin inhibits proliferation and migration of LECs
in vitro
The effect of rapamycin on VEGF-C driven proliferation of
the LYVEþ LEC fraction of human dermal microvascular
endothelial cell (HDMEC), identified by standard flow
cytometry, was tested in a bromodeoxyuridine (BrdU)
incorporation assay. Rapamycin inhibited proliferation in a
concentration-dependent manner (Figure 4a). A rapamycin
concentration as low as 1 ng/ml resulted in an B50%
inhibition of cell proliferation. Concentrations of 10 ng/ml or
above virtually abrogated cell proliferation. As migration is
an integral part of the lymphangiogenic process, we also
investigated the migratory activity of isolated LECs following
treatment with rapamycin. Indeed, rapamycin also resulted in
a significant reduction in the migratory activity of the
isolated cells (Figure 4b). These data demonstrate that
rapamycin significantly inhibits both LEC proliferation and
migration in a concentration range that is highly clinically
relevant for transplant patients (5–20 ng/ml).
Rapamycin inhibits VEGF-A and VEGF-C driven
phosphorylation of the p70S6 kinase in LECs
Mechanistically, we investigated whether the antiproliferative
effect of rapamycin on LECs is generated through inhibition
of p70S6 kinase phosphorylation. Western blot analysis
revealed that mTOR inhibition virtually abolished VEGF-C-
stimulated phosphorylation of the p70S6 kinase in isolated
LECs (Figure 5a and b). We also investigated the ability of
rapamycin to block p70S6 kinase phosphorylation in the
LECs stimulated with different VEGF isoforms known to
primarily activate either the vascular endothelial growth
factor receptor (VEGFR)-2 (VEGF-A) or the VEGFR-3
(VEGF-C*). Both VEGF-A and VEGF-C exhibited a solid
phosphorylation of the p70S6 kinase in LECs. In contrast,
treatment with VEGF-C*, which selectively activates VEGFR-
3, resulted in a more modest phosphorylation of the p70S6
kinase. In either case, however, the phosphorylation was
abrogated by treatment with rapamycin indicating that
mTOR-mediated phosphorylation of the p70S6 kinase is
crucial for both the VEGF-A- and VEGF-C-mediated
proliferation of LECs.
DISCUSSION
The salient findings of this study are that the mTOR
inhibition potently decreases regenerative and neoplastic
lymphangiogenesis. The antilymphangiogenic effect during
tissue regeneration resulted in a prolonged occurrence of
lymphedema in rapamycin-treated animals emphasizing
the clinical relevance of the antilymphangiogenic effect of
mTOR inhibition in a transplant setting. Of note, the
observed in vivo effects were not secondary to impaired
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Figure 4 | Rapamycin inhibits proliferation and migration of LECs
in vitro. (a) Proliferating LECs were defined as BrdUþ LYVE-1þ
HDMEC and are located in the upper right quadrant. Quantitative
analysis of three independent experiments indicates a
concentration-dependent inhibition of the proliferation of LECs.
Representative scatter plots for BrdU (FITC) and LYVE-1 (PerCP)
two-color flow cytometry are shown for cells with and without
rapamycin treatment. (b) The migratory activity of isolated LECs was
investigated using a modified Boyden chamber assays with the upper
chamber covered with MatrigelTM. The number of migrated cells was
assessed after 24 h. The data represent the results of three
independent experiments performed at least in duplicates.
b
a Phosphorylated
p70S6 kinase
Rapa
Actin
VEGF-C
– + – +
Rad001
– +
Control
Unstim VEGF-C VEGF-C* VEGF-A
Rapa – – – –++ ++
Stimulation
Phosphorylated
p70S6 kinase
Actin
Figure 5 | VEGF-A and VEGF-C lead to mTOR-dependent
phosphorylation of the p70S6 kinase. (a) Western blot analysis of
magnetic activated cell sorting-isolated LECs revealed strong
phosphorylation of the p70S6 kinase following stimulation with
VEGF-C. mTOR inhibition with either rapamycin or RAD-001
completely abolished the phosphorylation of the p70S6kinase in
response to stimulation with VEGF-C. (b) A similar stimulation of the
phosphorylation of the p70S6 was obtained by VEGF-A, whereas the
mutant VEGF-C*, a selective activator of the VEGFR-3, stimulated
the phosphorylation of the p70S6 kinase to a lesser extent.
Irrespective of the stimulatory signal, however, the enhanced
phosphorylation of the p70S6 kinase was abrogated by simultaneous
pretreatment with the mTOR inhibitor rapamycin. Representative
blots are shown.
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wound healing but rather due to direct antilymphangiogenic
effects. Indeed, the potent antilymphangiogenic effect of
rapamycin was confirmed in a wound-healing independent
MatrigelTM plug assay as well as a reduced LEC proliferation
and migration in vitro using clinically relevant concentra-
tions. Mechanistically, rapamycin administration, in analogy
to our previous studies in hemangiogenesis, impairs down-
stream signaling of VEGF-A through inhibition of the
mTOR/p70S6K pathway in LECs. Even more important,
however, we show here for the first time that rapamycin also
interferes with the intracellular pathway activation of LEC by
VEGF-C, the main initiator of lymphangiogenesis. Finally,
our data indicate that the antilymphangiogenic activity is not
restricted to a specific mTOR inhibitor rather than is a
general phenomenon of mTOR inhibition. All effects could
be elicited with both clinically approved mTOR inhibitors
rapamycin (sirolimus, RapamuneTM) and RAD-001 (ever-
olimus, CerticanTM).
Our findings bear important clinical relevance as mTOR
inhibitors are increasingly used in immunosuppressive regi-
mens following organ transplantation to prevent acute and
chronic CNI nephrotoxicity.14 However, while providing
similar immunosuppressive efficacy, their use as a first-line
agents has been challenged by the observed negative effects
on postoperative wound healing. Wound edema, wound
dehiscence, anastomosis insufficiency and the development
of lymphoceles are more frequently observed in mTOR
inhibitor-based immunosuppressive regimes compared with
conventional CNI treatment. This clinical experience with the
use of mTOR inhibitors during the early post-transplant
phase is suggestive for a potential antilymphangiogenic effect
of mTOR inhibitors. Moreover, even during the later phase
following transplantation well beyond the completion of
wound healing, lymph edemas at remote locations can
complicate mTOR inhibitor-based immunosuppression.6–9
Of note, in patients with this adverse effect elicited by a
mTOR treatment, withdrawal of the drug regularly leads to a
regression of these edemas. Our models of regenerative
lymphangiogenesis recapitulate some of the above-men-
tioned problems and show that the postoperative wound
healing problems can at least in part attributed to
antilymphangiogenic effects. The skin flap model as well as
wound healing assays after skin biopsy (data not shown)
suggest that inhibition of lymphangiogenesis is largely
independent of the primary wound closure by granulation/
scar tissue. These data are further corroborated by the clear
inhibition of lymphangiogenesis into MatrigelTM plugs.
Furthermore, our in vitro data show an extremely high
sensitivity of LECs for mTOR inhibitors. Even at very low
concentrations (5–10 ng/ml), far below fibroblast and most
tumor cells are affected rapamycin led to an almost complete
inhibition of cell proliferation. Taken together, the clinical
experience with this new class of immunosuppressive agents
in association with our experimental findings strongly
support the idea of antilymphangiogenesis in the pathogen-
esis of some of the mTOR inhibitor induced adverse effects.
On the other hand, lymphatic vessels play a major role in
cancer biology, as the spread of tumor cells to lymph nodes
implicates the lymphatic system as an important route of
metastasis and is often an early event in metastatic disease.
Therefore, the presence of tumor cells in local lymph nodes is
significant for the staging of cancer and largely determines
the outcome of tumor patients. It was long supposed that
lymphatic metastasis was a passive process whereby detached
tumor cells reached lymph nodes via drainage through pre-
existing local lymphatic vessels. More recently, it is becoming
more apparent that lymphangiogenesis contributes actively
to metastasis. Importantly, antilymphangiogenic strategies
improved survival in animal tumor models by reducing
tumor metastasis.15 First clinical evidence for an antilym-
phatic effect of rapamycin relates to the therapeutic
experience in Kaposi sarcomas.16 Kaposi sarcomas are
characterized by a high expression of VEGFR-3 suggesting a
lymphatic origin of these tumors.17 Interestingly, in the
instance of developing Kaposi sarcomas, conversion to an
mTOR inhibitor-based immunosuppression commonly re-
sults in regression of these Kaposi sarcomas further
corroborating our principle idea that rapamycin may inhibit
lymphangiogenesis. Therefore, the antilymphangiogenic as
well as antiangiogenic effects of mTOR inhibition may well
translate into a reduced incidence of clinically apparent
malignancies through reduced tumor growth and lymphatic
metastasis, respectively. Indeed, we already demonstrated in
our previous experimental studies that rapamycin reduces
lymphatic metastasis in a CT26 colon cancer and a L3.6pl
pancreatic cancer model.11 Here, we show in a murine
lymphangioma model that rapamycin significantly inhibits
the development and progression of these benign tumors,
suggesting a therapeutic potential of mTOR inhibitors in
benign and malignant lymphoproliferative diseases. Thus, the
antilymphangiogenic effects of mTOR inhibition complicat-
ing the early phase after transplantation may actually be
advantageous during later stages to prevent the development,
progression, and metastasis of certain tumor entities. Indeed,
increasing evidence suggests that mTOR inhibitors reduce the
high rate of de novo malignancies after organ transplantation.
In conclusion, here we demonstrate that mTOR inhibitors
act as antilymphangiogenic agents resulting in adverse effects
with respect to postoperative wound healing and edema
formation. Therefore, early mTOR inhibition following tissue
injury should be avoided. Our data provide the rationale for a
delayed used of mTOR inhibitors following surgical inter-
ventions such as organ transplantation. Currently, several
transplantation centers, including our own, are investigating
newly developed early conversion protocols. These protocols
are designed to avoid the early side effects of mTOR
inhibitors which are, as shown here, very likely to be at least
in part related to their antilymphangiogenic properties while
maintaining the beneficial effects related to the long-term use
of mTOR inhibitors. Moreover, the antilymphangiogenic
properties of rapamycin and its derivates may actually
provide additional therapeutic value for the prevention and
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treatment of malignancies, respectively. Currently, mTOR
inhibitors are tested in phase I and II trials for their
antitumoral effects in a variety of cancer entities. As no
pharmacological modulator of lymphangiogenesis has been
established to date,18 mTOR inhibitors may indeed serve as a
valuable tool to modulate lymphangiogenesis in different
pathological conditions.
MATERIALS AND METHODS
Murine skin flap model
The effect of rapamycin on lymphatic vessel regeneration was
examined in a murine skin flap assay as described elsewhere.19
Briefly, under anesthesia (ketamine, xylazine) nude NMRI-mice
(Harlan Winkelmann, Borchen, Germany) received an approxi-
mately 1 cm2 3/2 oval skin incision to create an epigastric flap.
Incisions were closed with single stitched maxon sutures. Loss of
lymphatic drainage across the flap was confirmed by intradermal
injection of 50 ml of Patent Blue V (2.5%; Guerbet, Roissy, France)
into the center of the flap. After surgery, animals were then
randomized for treatment with vehicle or rapamycin. Rapamycin
(RapamuneTM oral solution dissolved in tap water; 5 mg/kg/day) was
orally administered via the drinking water. Control mice received
tap water instead. Previous experiments indicated that this
rapamycin concentration results in clinically relevant rapamycin
blood levels (5–20 ng/ml) (Table 2; high-performance liquid
chromatography measurements; courtesy of Dr Vogeser, Central
Laboratory, Klinikum Großhadern, Munich, Germany). After 4
weeks, 50ml of Patent Blue was intradermally injected into the flap.
The blue lymphatic vessels were counted after 15 min. All lymphatic
vessels that crossed the scar area of the flap incision were considered
as crossing vessels. Lymphatic vessels draining Patent Blue caudal of
the flap were considered as collateral vessels. After 20 min, lymphatic
drainage of Patent Blue was assessed by exposing the axillary lymph
nodes. If blue color was detectable in the node, it was considered as a
positive lymph node.
Murine MatrigelTM plug assay
To determine the effect of rapamycin on lymphatic sprouting in vivo,
a MatrigelTM plug assay was carried out as described previously.20
Balb/c mice were anesthetized as described above. An area around the
left hip was shaved and an amount of 500ml of MatrigelTM (Becton
Dickinson, Two Oak Park, Bedford, MA, USA) supplied with
VEGF-C (R&D Systems, Minneapolis, MN, USA) at a concentration
of 100 ng/ml was injected subcutaneously in the left inguinal area.
After 21 days, mice were killed for harvesting of the plug followed by
embedding in paraffin and preparation of 5mm sections. Lymphatic
vessels were identified by immunohistochemistry using rabbit
primary antibodies against murine LYVE-1 (Acris Antibodies) and
a biotinylated goat secondary antibody to rabbit IgG (DakoCytoma-
tion, Glostrup, Denmark). Fluorescence labeling was performed with
Texas Red Avidin D (Vector, Burlingame, CA, USA) and nuclei were
stained with Vectashield-DAPI (Vector). Sections were analyzed
using an Axiovert 40 fluorescence microscope (Zeiss, Oberkochen,
Germany), the AxioCam MRm camera (Zeiss), and AxioVision 4.4
Software (Zeiss). Ten randomly selected fields from each section were
counted to assess the number of lymphatic vessels.
Lymphangioma assay
C57/BL6 mice were intraperitoneally injected twice on days 0 and 14
with 200 ml of emulsified (1:1 with phosphate-buffered saline)
incomplete Freund’s adjuvant and simultaneously treated with oral
rapamycin or control. After 4 weeks, intra-abdominal angiomas
were assessed and then surgically removed for histological analysis.
The tissue was fixed in 10% formalin, embedded in paraffin, and cut
into sections of 5 mm thickness. Lymphatic vessels were identified by
immunostaining for LYVE-1. To further evaluate the effect of
rapamycin and the widely used immunosuppressive agent cyclo-
sporine on lymphangioma growth, independent of the immuno-
suppressive effects on T cells, we performed experiments in athymic
NMRI nu/nu mice (8–10 weeks). The therapeutic effect of rapamycin
on established lymphangiomas that were generated by injection of
Freund’s adjuvant on days 0 and 14 followed by randomization to
treatment with rapamycin or control on day 16.
Cell culture experiments
HDMECs were purchased from PromoCell (Heidelberg, Germany)
and cultivated in NUNClonCell T-75 or T-175 flasks (NUNC,
Roskilde, Denmark) for up to four passages using Endothelial Cell
Growth Medium MV (PromoCell).
Isolation of LECs. LECs were isolated by magnetic bead sorting.
For this purpose, HDMECs were trypsinized, washed, and
resuspended in phosphate-buffered saline. Then, cells were incu-
bated with a biotinylated VEGFR-3 antibody (R&D Systems) for
30 min at 41C. After another washing step, the cells were incubated
with streptavidin-MicroBeads (Miltenyi Biotech, Bergisch Gladbach,
Germany) for 20 min at room temperature. Finally, VEGFR-3þ cells
were enriched using a MidiMACS magnet and MS columns
(Miltenyi Biotech). All magnetic activated cell-sorting procedures
were performed according to the manufacturer’s instructions. The
purity of isolated cells was determined by standard flow cytometry
analysis using a primary antibody against human podoplanin (Acris,
Hiddenhausen, Germany) and a secondary fluorescein isothiocya-
nate-labeled antibody against mouse IgG1 (BD Pharmingen, San
Diego, CA, USA). The purity of isolated LECs exceeded 95%.
Cell proliferation. HDMECs were incubated with BrdU
(10mM) for 2 h. Then, cells were washed in phosphate-buffered
saline and incubated with anti-BrdU-fluorescein isothiocyanate
(1:50) for 20 min according to the manufacturer’s instructions (BD
Pharmingen). LECs were identified by simultaneous staining for the
lymphatic marker LYVE-1. For this purpose, HDMECs were
incubated with biotinylated antibodies for LYVE-1 (R&D Systems)
and PerCP-labeled streptavidin (BD Pharmingen).
Migratory capacity of LECs. A total of 2.5 105 pretreated
LECs were resuspended in 250ml of MV Basal Medium (PromoCell)
containing 2% fetal calf serum and placed in the upper chamber of a
modified Boyden chamber filled with MatrigelTM (BioCoats
invasion assay, 8 mm pore size, Becton Dickinson Labware). The
upper chamber was placed in a 24–well culture dish containing
500 ml of the medium described above supplemented with 100 ng/ml
VEGF-C and rapamycin at a concentration of 20 ng/ml. After 24 h of
incubation at 371C, transmigrated cells were pelleted and scored
using a Neubauer chamber.
Table 2 | Rapamycin blood levels in mice following oral
treatment via the drinking water (nX4 per group)
Rapamycin oral dose
(mg/kg/day)
Rapamycin blood levels
(ng/ml)
1.0 1.770.3
2.0 2.770.4
5.0 14.473.7
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p70S6 kinase phosphorylation assay. Phosphorylation of the
p70S6 kinase at the Thr389 site, the specific phosphorylation site of
mTOR,21 was assessed by Western blotting. Isolated LECs were
cultured in Endothelial Cell Growth Medium MV containing all
supplements from the original kit except for growth factors and
added VEGF-C (R&D Systems) at a concentration of 100 ng/ml,
starved (‘diet’ medium: serum and supplement depleted) for 16 h,
and subsequently cultivated for 1 h with diet medium containing
rapamycin (20 ng/ml) or control. Following this conditioning
period, LECs were stimulated with recombinant VEGF-A165
(50 ng/ml; PromoCell), recombinant VEGF-C (200 ng/ml; R&D
Systems; binding to both VEGFR-2 and VEGFR-3), or recombinant
VEGF-C in which Cys156 is replaced by a Ser residue (VEGF-C*;
R&D Systems) as a selective agonist of VEGFR-3.22,23 After a 30-min
incubation period, cells were lyzed (Tris (tris(hydroxymethyl)
aminomethane)–HCl 20 mM, pH 7.5, NaCl 150 mM, Na2EDTA
(ethylenediaminetetraacetic acid) 1 mM, EGTA (ethylene glycol
tetraacetic acid) 1 mM, 1% Triton-100, sodium pyrophosphate
2.5 mM, b-glycerophosphate 1 mM, leupeptin 1 mg/ml, Na3VO4
1 mM, phenylmethylsulfonyl fluoride 1 mM) and protein degradation
was inhibited by protease inhibitor tablets (Cell Signaling Technol-
ogy, Beverly, MA, USA). Equal amounts of protein extract were
separated on polyacrylamide-sodium dodecyl sulfate gels (8%),
transferred onto a polyvinylidene difluoride membrane, and probed
with rabbit-phospho (Thr389) p70S6 kinase antibody (Cell Signaling
Technology). Primary antibody binding was detected with a goat
anti-rabbit horseradish peroxidase-conjugated secondary antibody
(sc-2004; Santa Cruz Biotechnology, St Cruz, CA, USA) in an
enhanced chemiluminescence Western blotting system (Amersham,
GE Healthcare Europe, Munich, Germany). To confirm total protein
loading, total actin was detected using a mouse antibody against all
six isoforms of actin (ICN Pharmaceuticals Inc., Cappel Product,
Aurora, OH, USA) as the primary antibody, followed by a sheep
anti-mouse IgG horseradish peroxidase-conjugated secondary anti-
body (Amersham).
Statistical analysis
Results for continuous variables are expressed as means7s.d.
Treatment groups were compared with the independent samples t-
test. In the case of non-normal distribution, the Mann–Whitney U-
test was used. Pair-wise multiple comparisons were performed with
the t-test (two-sided) with LSD adjustment. Po0.05 were
considered statistically significant. All analyses were performed with
SPSS 11.5 (SPSS Inc., Chicago, IL, USA).
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